146 related articles for article (PubMed ID: 38611052)
1. MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma.
Barnett AE; Ozair A; Bamashmos AS; Li H; Bosler DS; Yeaney G; Ali A; Peereboom DM; Lathia JD; Ahluwalia MS
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611052
[No Abstract] [Full Text] [Related]
2. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
4. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
7. Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
Buyuktepe M; Kaplan I; Bayatli E; Dogan H; Ugur HC
J Neurooncol; 2023 Aug; 164(1):171-177. PubMed ID: 37474746
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
10. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.
Brigliadori G; Foca F; Dall'Agata M; Rengucci C; Melegari E; Cerasoli S; Amadori D; Calistri D; Faedi M
J Neurooncol; 2016 Jun; 128(2):333-9. PubMed ID: 27029617
[TBL] [Abstract][Full Text] [Related]
11. Correlation of commercially available quantitative
Dovek L; Nguyen NT; Ozer BH; Li N; Elashoff RM; Green RM; Liau L; Nghiemphu PL; Cloughesy TF; Lai A
Neurooncol Pract; 2019 May; 6(3):194-202. PubMed ID: 31386024
[TBL] [Abstract][Full Text] [Related]
12. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of partial
Torre M; Wen PY; Iorgulescu JB
Neurooncol Pract; 2023 Apr; 10(2):126-131. PubMed ID: 36970171
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
[TBL] [Abstract][Full Text] [Related]
17. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
[TBL] [Abstract][Full Text] [Related]
18. Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Cucchiara F; Luci G; Giannini N; Giorgi FS; Orlandi P; Banchi M; Di Paolo A; Pasqualetti F; Danesi R; Bocci G
Pharmacol Res; 2022 Jul; 181():106290. PubMed ID: 35680010
[TBL] [Abstract][Full Text] [Related]
19. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
